Recent IP Developments across Europe, China & Australia
Partners: Bird & Bird The webinar series bring together leading legal experts who will share the latest legal updates, decisions, and insights in live sessions over the week, ensuring you have the global perspective to stay ahead of the game. Webinar Date: 23 rd November 2023 | Timings: 2:30 pm IST/9:00 am GMT Agenda: The […]
Bird & Bird
The webinar series bring together leading legal experts who will share the latest legal updates, decisions, and insights in live sessions over the week, ensuring you have the global perspective to stay ahead of the game.
Webinar Date: 23 rd November 2023 | Timings: 2:30 pm IST/9:00 am GMT
The webinar will discuss most important patent/pharma cases decided in the past year and will focus on
The Unified Patent Court – the first 6 months
Plausibility post-G2/21: Apixaban in the U.K.
Recent patent linkage decisions e.g.
- AstraZeneca vs Sichuan Guowei
- Chugai vs Wenzhou Haihe
- Sumitomo Dainippon vs Zhejiang Huahai
Centralised Drug Procurement System and the proposed Shanghai implementation rules.
First CNIPA patent infringement decision- Boehringer Ingelheim vs Sunshine Lake.
Current climate in Australia for defending PIs:
- Key factors in play in defending a PI application.
- Preparing to launch at risk to maximize compensation if PI granted.
Dissecting the judgment in Rivaroxaban – Bayer v Sandoz –November 2023.
Mark Hilton (firstname.lastname@example.org)
Mark is a partner in Bird & Bird international Intellectual Property Group and co-head of International Life Sciences & Healthcare Group.
He specialises in patent litigation and advise in the area of pharmaceuticals, biosimilars, biotechnology (including in food), chemicals and medical devices.
In the course of over 20 years of experience of patent litigation, he has been involved in devising successful litigation strategies and co-ordinating complex multi-jurisdictional disputes for clients.
He has written and spoken on a number of IP topics and is an associate of the Chartered Institute of Patent Attorneys (CIPA) and a member of the Law Society of Ireland.
Alison Wong (email@example.com)
Alison is partner in Bird & Bird Intellectual Property Group in Hong Kong and Head of Life Sciences & Healthcare Sector Group in Asia, Alison has 24 years’ experience in advising clients in the life sciences, healthcare, food & beverage and retail & consumer sectors.
She advises pharmaceutical, biotechnology and medical device companies on regulatory issues, market authorisations, clinical trial agreements and public sector procurement. In recent years, she has also been involved in negotiating R&D agreements and technology licensing for life sciences companies.
She is ranked as a leading IP and life sciences lawyer by the major industry publications and legal directories including Chambers and Legal 500. She has also been recognised by Managing IP, ALB China IP, World IP Review, WTR 1000, IAM Patent, and China Law & Practice.
In addition to being a regular speaker at international conferences, she is involved in lobbying the HKSAR government and the HKSAR Legislative Council on copyright law reform. I am a member of APAA, INTA and the HKTMP.
Jane Owen (firstname.lastname@example.org)
Jane is a partner and head of Bird & Bird Intellectual Property Group in Sydney where she uses her deep-level experience of complex IP strategy and disputes to advise clients from a range of IP-rich industries.
She uses her industry and IP knowledge, to assist clients in structuring IP driven transactions, delivering practical, future-proof strategic advice and commercial documentation.
Before joining Bird & Bird in 2015, she was a partner at various law firms in Sydney. Today, she often presents on IP issues at continuing legal education and industry events.